Values of tumor-infiltrating lymphocytes (TILs), CD8+ TILs, and PDL-1 for predicting pathological complete response and prognosis in HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab.

Authors

Sasagu Kurozumi

Breast and Endocrine Surgery, Gunma University Hospital and Division of Breast Surgery, Saitama Cancer Center, Gunma, Japan

Sasagu Kurozumi , Kenichi Inoue , Masafumi Kurosumi , Hiroshi Matsumoto , Yuji Hayashi , Katsunori Tozuka , Kazuyuki Kubo , Kei Komatsu , Ken Takai , Shigenori E. Nagai , Hanako Oba , Jun Horiguchi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Association between distinct intratumoral and stromal tumor infiltrating immune cells and pathologic complete response (pCR) in different breast cancer subtypes after neoadjuvant chemotherapy (NAC).

First Author: Lucia Gonzalez-Cortijo

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial.

First Author: Sherene Loi

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Does race influence long-term outcomes after neoadjuvant chemotherapy in breast cancer: A National Cancer Database analysis.

First Author: Arya Mariam Roy

insert_chart_outlined

Poster

2021 Genitourinary Cancers Symposium

bookmark_border

KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).

First Author: Matt D. Galsky